AbbVie (ABBV) is planning to launch an offering of as many as seven series of senior notes, according to a regulatory filing on Tuesday.

AbbVie said it intends to use the net proceeds to repay amounts under its 364-day delayed draw term loan facility, of which $2 billion is currently outstanding, as well as for general corporate purposes, which may include the repayment or repurchase of outstanding debt.

The longest part of the offering is a bond maturing in 2066, which could potentially be priced at 1.25 percentage points over the benchmark, Bloomberg reported on Tuesday, citing a source with knowledge of the deal.